microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
Abstract
1. Introduction
2. Results
2.1. Expression Profiles of miR-21, miR-221, miR-155, and miR-126 in PDAC In Vitro
2.2. Development of miR-21 KO MiaPaca-2 and Panc-1 Cell Lines
2.3. miR-21 Kos Reduce Expression Levels of EMT-Related Markers
2.4. miR-21 Kos Diminish Expressions of CSC Markers in PDAC
2.5. Flow Cytometry Analysis of PCSCs Expression in PDAC miR-21 KO Cells
2.6. miR-21 KO Reduce Cellular Invasion in Panc-1 and MiaPaca-2 Cells
3. Discussion
4. Materials and Methods
4.1. Cell Culture and CRISPR/Cas9 Assay
4.2. RNA Extraction and RT-qPCR
4.3. Immunostaining
4.4. Flow Cytometry Analysis
4.5. Matrigel Invasion and Proliferation Assays
4.6. Colony Formation
4.7. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
ALDH-1 | Aldehyde dehydrogenase-1 |
CA 19-9 | Carbohydrate antigen 19-9 |
CSCs | Cancer stem cells |
CXCR4 00 | CX-C chemokine receptor type 4 |
DMEM | Dulbecco’s Modified Eagle’s Medium |
EMT | Epithelial–mesenchymal transition |
FBS | Fetal bovine serum |
FoxM1 | Forkhead box protein M1 |
HPDE | Human pancreatic ductal epithelial cell line |
IDT | Integrated DNA Technologies |
IPMN | Intraductal papillary mucinous neoplasm |
KOs | Knockouts |
MAPK | Mitogen-activated protein kinase |
MDSCs | Myeloid-derived suppressor cells |
miRs | microRNAs |
mTOR | Mammalian target of rapamycin |
nMDSCs | Neutrophil-like heterogeneous myeloid-derived suppressor cells |
NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
oncomiR | Oncogenic miR |
PanIN | Pancreatic intraepithelial neoplasia |
PCa | Pancreatic cancer |
PCSCs | Pancreatic cancer stem cells |
PDAC | Pancreatic ductal adenocarcinoma |
PDCD4 | Programmed cell death 4 |
PDGF | Platelet-derived growth factor |
PI3K | Phosphoinositide-3-kinase |
PNI | Perineural invasion |
RPII | RNA polymerase 2 |
SD | Standard Deviation |
SHH | Sonic Hedgehog |
TNM | Tumor-Node-Metastasis |
UTRs | Untranslated regions |
VEGF | Vascular endothelial growth factor |
ZEB1 | Zinc Finger E-box binding homeobox 1 |
References
- Carrato, A.; Falcone, A.; Ducreux, M.; Valle, J.W.; Parnaby, A.; Djazouli, K.; Alnwick-Allu, K.; Hutchings, A.; Palaska, C.; Parthenaki, I.; et al. A systematic review of the burden of pancreatic cancer in. Europe: Real-world impact on survival, quality of life and costs. J. Gastrointest. Cancer 2015, 46, 201–211. [Google Scholar] [CrossRef] [PubMed]
- Von Hoff, D.D.; Korn, R.; Mousses, S. Pancreatic cancer—Could it be that simple? A different context of vulnerability. Cancer Cell 2009, 16, 7–8. [Google Scholar] [CrossRef][Green Version]
- Gall, F.P.; Kessler, H.; Hermanek, P. Surgical treatment of ductal pancreatic carcinoma. Eur. J. Surg. Oncol. 1991, 17, 173–181. [Google Scholar]
- Srivastava, S.K.; Srivastava, S.K.; Arora, S.; Singh, S.; Bhardwaj, A.; Averett, C.; Singh, A.P. MicroRNAs in pancreatic malignancy: Progress and promises. Cancer Lett. 2014, 347, 167–174. [Google Scholar] [CrossRef] [PubMed]
- Cartwright, T.; Richards, D.A.; Boehm, K.A. Cancer of the pancreas: Are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 2008, 15, 308–313. [Google Scholar] [CrossRef]
- Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [Google Scholar] [CrossRef]
- Lin, S.; Gregory, R.I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 2015, 15, 321–333. [Google Scholar] [CrossRef]
- Turchinovich, A.; Tonevitsky, A.G.; Burwinkel, B. Extracellular miRNA: A collision of two paradigms. Trends Biochem. Sci. 2016, 41, 883. [Google Scholar] [CrossRef]
- Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92–105. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Li, A.; Hong, S.M.; Hruban, R.H.; Goggins, M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin. Cancer Res. 2012, 18, 981–992. [Google Scholar] [CrossRef] [PubMed]
- Zhao, X.; Ren, Y.; Cui, N.; Wang, X.; Cui, Y. Identification of key microRNAs and their targets in exosomes of pancreatic cancer using bioinformatics analysis. Medicine 2018, 97, e12632. [Google Scholar] [CrossRef]
- Slack, F.J.; Weidhaas, J.B. MicroRNA in cancer prognosis. N. Engl. J. Med. 2008, 359, 2720–2722. [Google Scholar] [CrossRef]
- Gilles, M.; Hao, L.; Huang, L.; Rupaimoole, R.; Lopez-Casas, P.P.; Pulver, E.; Jeong, J.C.; Muthuswamy, S.K.; Hidalgo, M.; Bhatia, S.N.; et al. Personalized RNA medicine for pancreatic cancer. Clin. Cancer Res. 2018, 24, 1734–1747. [Google Scholar] [CrossRef] [PubMed]
- Galasso, M.; Sandhu, S.K.; Volinia, S. MicroRNA expression signatures in solid malignancies. Cancer J. 2012, 18, 238–243. [Google Scholar] [CrossRef] [PubMed]
- Hussain, S.P. Pancreatic cancer: Current progress and future challenges. Int. J. Biol. Sci. 2016, 12, 270. [Google Scholar] [CrossRef] [PubMed]
- Kasaka, N.; Iguchi, H.; Ochiya, T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101, 2087–2092. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Chen, J.; Chang, P.; LeBlanc, A.; Li, D.; Abbruzzesse, J.L.; Frazier, M.L.; Killary, A.M.; Sen, S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. 2009, 2, 807–813. [Google Scholar] [CrossRef]
- Kojima, M.; Sudo, H.; Kawauchi, J.; Takizawa, S.; Kondou, S.; Nobumasa, H.; Ochiai, A. MicoRNA markers for diagnosis of pancreatic and biliary-tract cancers. PLoS ONE 2015, 10, e0118220. [Google Scholar] [CrossRef]
- Chan, A.; Prassas, I.; Dimitromanolakis, A.; Brand, R.E.; Serra, S.; Diamandis, E.P.; Blasutig, I.M. Validation of biomarkers that complement ca19.9 in detecting early pancreatic cancer. Clin. Cancer Res. 2014, 20, 5787–5795. [Google Scholar] [CrossRef]
- Sawabu, N.; Watanabe, H.; Yamaguchi, Y.; Ohtsubo, K.; Motoo, Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 2004, 28, 263–267. [Google Scholar] [CrossRef]
- Schultz, N.A.; Dehlendorff, C.; Jensen, B.V.; Bjerregaard, J.K.; Nielsen, K.R.; Bojesen, S.E.; Calatayud, D.; Nielsen, S.E.; Yilmaz, M.; Holländer, N.H.; et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014, 311, 392–404. [Google Scholar] [CrossRef]
- Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030–1037. [Google Scholar] [CrossRef] [PubMed]
- Li, C.; Lee, C.J.; Simeone, D.M. Identification of human pancreatic cancer stem cells. Methods Mol. Biol. 2009, 568, 161–173. [Google Scholar]
- Niess, H.; Camaj, P.; Renner, A.; Ischenko, I.; Zhao, Y.; Krebs, S.; Mysliwietz, J.; Jäckel, C.; Nelson, P.J.; Blum, H.; et al. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Target Oncol. 2015, 10, 215–227. [Google Scholar] [CrossRef]
- Kim, M.P.; Fleming, J.B.; Wang, H.; Abbruzzese, J.L.; Choi, W.; Kopetz, S.; McConkey, D.J.; Evans, D.B.; Gallick, G.E. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 2011, 6, e20636. [Google Scholar] [CrossRef] [PubMed]
- Klonisch, T.; Wiechec, E.; Hombach-Klonisch, S.; Ande, S.R.; Wesselborg, S.; Schulze-Osthoff, K.; Los, M. Cancer stem cell markers in common cancers—Therapeutic implications. Trends Mol. Med. 2008, 14, 450–460. [Google Scholar] [CrossRef] [PubMed]
- Marcato, P.; Dean, C.A.; Pan, D.; Araslanova, R.; Gillis, M.; Joshi, M.; Helyer, L.; Pan, L.; Leidal, A.; Gujar, S.; et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29, 32–45. [Google Scholar] [CrossRef] [PubMed]
- Miranda-Lorenzo, I.; Dorado, J.; Lonardo, E.; Alcala, S.; Serrano, A.G.; Clausell-Tormos, J.; Cioffi, M.; Megias, D.; Zagorac, S.; Balic, A.; et al. Intracellular autofluorescence: A biomarker for epithelial cancer stem cells. Nat. Methods 2014, 11, 1161–1169. [Google Scholar] [CrossRef]
- Valle, S.; Martin-Hijano, L.; Alcalá, S.; Alonso-Nocelo, M.; Sainz, B., Jr. The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer. Cancers 2018, 10, 33. [Google Scholar] [CrossRef]
- Santamaria, S.; Delgado., M.; Kremer., L.; Garcia-Sanz, J.A. Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible? Front. Immunol. 2017, 8, 1509. [Google Scholar] [CrossRef] [PubMed]
- Plaks, V.; Kong, N.; Werb, Z. The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015, 16, 225–238. [Google Scholar] [CrossRef]
- Dawood, S.; Austin, L.; Cristofanilli, M. Cancer stem cells: Implications for cancer therapy. Oncology 2014, 28, 1101–1107, 1110. [Google Scholar] [PubMed]
- Lei, Y.; Zhang, D.; Yu, J.; Dong, H.; Zhang, J.; Yang, S. Targeting autophagy in cancer stem cells as an anticancer therapy. Cancer Lett. 2017, 393, 33–39. [Google Scholar] [CrossRef]
- Cojoc, M.; Mäbert, K.; Muders, M.H.; Dubrovska, A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin. Cancer Biol. 2015, 31, 16–27. [Google Scholar] [CrossRef] [PubMed]
- Dalla Pozza, E.; Dando, I.; Biondani, G.; Brandi, J.; Costanzo, C.; Zoratti, E.; Fassan, M.; Boschi, F.; Melisi, D.; Cecconi, D.; et al. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bidirectionally convert into cancer stem cells. Int. J. Oncol. 2015, 46, 1099–1108. [Google Scholar] [CrossRef]
- Kalluri, R.; Weinberg, R.A. The basics of epithelial mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [Google Scholar] [CrossRef]
- Felipe Lima, J.; Nofech-Mozes, S.; Bayani, J.; Bartlett, J.M.S. EMT in breast carcinoma—A review. J. Clin. Med. 2016, 5, 65. [Google Scholar] [CrossRef]
- Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [Google Scholar] [CrossRef] [PubMed]
- Iacobuzio-Donahue, C.A.; Fu, B.; Yachida, S.; Luo, M.; Abe, H.; Henderson, C.M.; Vilardell, F.; Wang, Z.; Keller, J.W.; Banerjee, P.; et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 2009, 27, 1806–1813. [Google Scholar] [CrossRef] [PubMed]
- Winter, J.M.; Ting, A.H.; Vilardell, F.; Gallmeier, E.; Baylin, S.B.; Hruban, R.H.; Kern, S.E.; Iacobuzio-Donahue, C.A. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin. Cancer Res. 2008, 14, 412–418. [Google Scholar] [CrossRef]
- Renz, B.W.; D’Haese, J.G.; Werner, J.; Westphalen, C.B.; Ilmer, M. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). Med. Sci. 2017, 5, 14. [Google Scholar] [CrossRef]
- Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820–5828. [Google Scholar] [CrossRef]
- Buck, E.; Eyzaguirre, A.; Barr, S.; Thompson, S.; Sennello, R.; Young, D.; Iwata, K.K.; Gibson, N.W.; Cagnoni, P.; Haley, J.D. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 2007, 6, 532–541. [Google Scholar] [CrossRef] [PubMed]
- Maier, H.J.; Schmidt-Strassburger, U.; Huber, M.A.; Wiedemann, E.M.; Beug, H.; Wirth, T. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 2010, 295, 214–228. [Google Scholar] [CrossRef]
- Uysal-Onganer, P.; Kawano, Y.; Caro, M.; WalkeR, M.M.; Diez, S.; Darrington, R.S.; Waxman, J.; Kypta, R.M. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol. Cancer. 2010, 9, 55. [Google Scholar] [CrossRef] [PubMed]
- Arisan, E.D.; Rencuzogullari, O.; Freitas, I.L.; Radzali, S.; Keskin, B.; Kothari, A.; Warford, A.; Uysal-Onganer, P. Upregulated Wnt-11 and miR-21 Expression Trigger Epithelial Mesenchymal Transition in Aggressive Prostate Cancer Cells. Biology 2020, 9, 52. [Google Scholar] [CrossRef] [PubMed]
- Guo, X.; Wang, X.F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009, 19, 71–88. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Yao, M.; Fang, M.; Zheng, W.J.; Dong, Z.Z.; Pan, L.H.; Zhang, H.J.; Yao, D.F. Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2018, 17, 227–232. [Google Scholar] [CrossRef]
- Wang, X.; Liu, D.; Zhou, K.; Wang, B.; Liu, Q.; Deng, F.; Li, Q.; Ma, Y. Expression of Wnt-11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance. Pathol. Res. Pract. 2016, 212, 880–885. [Google Scholar] [CrossRef] [PubMed]
- Hotz, B.; Arndt, M.; Dullat, S.; Bhargava, S.; Buhr, H.J.; Hotz, H.G. Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clin. Cancer Res. 2007, 13, 4769–4776. [Google Scholar] [CrossRef]
- De Craene, B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13, 97–110. [Google Scholar] [CrossRef] [PubMed]
- Fedele, M.; Cerchia, L.; Chiappetta, G. The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas. Cancers 2017, 9, 134. [Google Scholar] [CrossRef] [PubMed]
- Klymkowsky, M.W.; Savagner, P. Epithelial-mesenchymal transition: A cancer researcher’s conceptual friend and foe. Am. J. Pathol. 2009, 174, 1588–1593. [Google Scholar] [CrossRef]
- Traub, P.G.; Perides, G.; Scherbarth, A.; Traub, U. Tenacious binding of lipids to vimentin during its isolation and purification from Ehrlich ascites neoplastic cells. FEBS Lett. 1985, 193, 217–221. [Google Scholar] [CrossRef]
- Naito, Y.; Iacobuzio-Donahue, C.A. Biomarker profiles associated with metastatic pancreatic cancer. Mod. Pathol. 2010, 23, 366A. [Google Scholar]
- Javle, M.M.; Gibbs, J.F.; Iwata, K.K.; Pak, Y.; Rutledge, P.; Yu, J.; Black, J.D.; Tan, D.; Khoury, T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann. Surg. Oncol. 2007, 14, 3527–3533. [Google Scholar] [CrossRef]
- Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017, 14, 611–629. [Google Scholar] [CrossRef]
- Rhim, A.D.; Mirek, E.T.; Aiello, N.M.; Maitra, A.; Bailey, J.M.; McCallister, F.; Reichert, M.; Beatty, G.L.; Rustgi, A.K.; Vonderheide, R.H.; et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148, 349–361. [Google Scholar] [CrossRef]
- Rao, C.V.; Mohammed, A. New insights into pancreatic cancer stem cells. World J. Stem Cells 2015, 7, 547–555. [Google Scholar] [CrossRef]
- Chalquest, R.R. Preveterinary requirements and admission to American veterinary colleges: Important changes. J. Am. Vet. Med. Assoc. 1986, 189, 27–29. [Google Scholar]
- Kure, S.; Matsuda, Y.; Hagio, M.; Ueda, J.; Naito, Z.; Ishiwata, T. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Int. J. Oncol. 2012, 41, 1314–1324. [Google Scholar] [CrossRef] [PubMed]
- Hruban, R.H.; Adsay, N.V.; Albores-Saavedra, J.; Anver, M.R.; Biankin, A.V.; Boivin, G.P.; Furth, E.E.; Furukawa, T.; Klein, A.; Klimstra, D.S.; et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Res. 2006, 66, 95–106. [Google Scholar] [CrossRef]
- Oshima, Y.; Suzuki, A.; Kawashimo, K.; Ishikawa, M.; Ohkohchi, N.; Taniguchi, H. Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 2007, 132, 720–732. [Google Scholar] [CrossRef] [PubMed]
- Wang, V.M.Y.; Ferreira, R.M.M.; Almagro, J.; Evan, T.; Legrave, N.; Zaw Thin, M.; Frith, D.; Carvalho, J.; Barry, D.J.; Snijders, A.P.; et al. CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth. Nat. Cell Biol. 2019, 21, 1425–1435. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.H.; Kim, H.; Hwang, J.-H.; Shin, E.; Lee, H.S.; Hwang, D.W.; Cho, J.Y.; Yoon, Y.S.; Han, H.S.; Cha, B.H. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. Pancreas 2014, 43, 380–388. [Google Scholar] [CrossRef]
- Liu, Y.; Wu, T.; Lu, D.; Zhen, J.; Zhang, L. CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer. Int. J. Biol. Markers 2018, 33, 308–313. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Zhao, H.; Gu, J.; Zheng, L. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): A systematic review and meta-analysis. Int. J. Clin. Exp. Pathol. 2015, 8, 12084–12092. [Google Scholar]
- Yi, J.M.; Guzzetta, A.A.; Bailey, V.J.; Downing, S.R.; Van Neste, L.; Chiappinelli, K.B.; Keeley, B.P.; Stark, A.; Herrera, A.; Wolfgang, C.; et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin. Cancer Res. 2013, 19, 6544–6555. [Google Scholar] [CrossRef]
- Deng, S.; Calin, G.A.; Croce, C.M.; Coukos, G.; Zhang, L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7, 2643–2646. [Google Scholar] [CrossRef]
- Zhou, X.; Zhou, X.; Wang, X.; Huang, Z.; Wang, J.; Zhu, W.; Shu, Y.; Liu, P. Prognostic value of miR-21 in various cancers: An updating meta-analysis. PLoS ONE 2014, 9, e102413. [Google Scholar] [CrossRef]
- Qu, K.; Zhang, X.; Lin, T.; Liu, T.; Wang, Z.; Liu, S.; Zhou, L.; Wei, J.; Chang, H.; Wang, Z.; et al. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: Evidence from comprehensive miRNA expression profiling analysis and clinical validation. Sci. Rep. 2017, 7, 1692. [Google Scholar] [CrossRef] [PubMed]
- Bao, B.; Ali, S.; Kong, D.; Sarkar, S.H.; Wang, Z.; Banerjee, S.; Aboukameel, A.; Padhye, S.; Philip, P.A.; Sarkar, F.H. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS ONE 2011, 6, e17850. [Google Scholar] [CrossRef] [PubMed]
- Su, A.; He, S.; Tian, B.; Hu, W.; Zhang, Z. MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS ONE 2013, 8, e71309. [Google Scholar] [CrossRef] [PubMed]
- Felli, N.; Fontana, L.; Pelosi, E.; Botta, R.; Bonci, D.; Facchiano, F.; Liuzzi, F.; Lulli, V.; Morsilli, O.; Santoro, S.; et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. USA 2005, 102, 18081–18086. [Google Scholar] [CrossRef] [PubMed]
- Shahbazi, J.; Lock, R.; Liu, T. Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis. Front. Genet. 2013, 4, 80. [Google Scholar] [CrossRef]
- Han, Z.; Chen, H.Y.; Fan, J.W.; Wu, J.Y.; Tang, H.M.; Peng, Z.H. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J. Cancer Res. Clin. Oncol. 2012, 138, 153–161. [Google Scholar] [CrossRef]
- Sasi, W.; Jiang, W.G.; Sharma, A.; Mokbel, K. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer 2010, 10, 178. [Google Scholar] [CrossRef]
- Zhang, J.; Li, H.; Yu, J.P.; Wang, S.E.; Ren, X.B. Role of SOCS1 in tumor progression and therapeutic application. Int. J. Cancer 2012, 130, 1971–1980. [Google Scholar] [CrossRef]
- Ryu, J.K.; Hong, S.M.; Karikari, C.A.; Hruban, R.H.; Goggins, M.G.; Maitra, A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010, 10, 66–73. [Google Scholar] [CrossRef]
- Yuan, W.; Guo, Y.Q.; Li, X.Y.; Deng, M.Z.; Shen, Z.H.; Bo, C.B.; Dai, Y.F.; Huang, M.Y.; Yang, Z.Y.; Quan, Y.S.; et al. MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway. Oncotarget 2016, 7, 60230–60244. [Google Scholar] [CrossRef]
- Liu, Y.; Zhou, Y.; Feng, X.; An, P.; Quan, X.; Wang, H.; Ye, S.; Yu, C.; He, Y.; Luo, H. MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways. Int. J. Oncol. 2014, 44, 203–210. [Google Scholar] [CrossRef]
- Li, N.; Tang, A.; Huang, S.; Li, Z.; Li, X.; Shen, S.; Ma, J.; Wang, X. miR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol. Cell. Biochem. 2013, 380, 107–119. [Google Scholar] [CrossRef]
- Wang, S.C.; Lin, J.K.; Wang, H.S.; Yang, S.H.; Li, A.F.; Chang, S.C. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int. J. Colorectal Dis. 2010, 25, 1185–1191. [Google Scholar] [CrossRef]
- Li, Z.; Li, N.; Wu, M.; Li, X.; Luo, Z.; Wang, X. Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol. Cell. Biochem. 2013, 381, 233–242. [Google Scholar] [CrossRef]
- Hu, M.; Xiong, S.; Chen, Q.; Zhu, S.; Zhou, X. Novel role of microRNA-126 in digestive system cancers: From bench to bedside (Review). Oncol. Lett. 2019, 17, 31–41. [Google Scholar] [CrossRef]
- Hasegawa, S.; Eguchi, H.; Nagano, H.; Konno, M.; Tomimaru, Y.; Wada, H.; Hama, N.; Kawamoto, K.; Kobayashi, S.; Nishida, N.; et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br. J. Cancer 2014, 111, 1572–1580. [Google Scholar] [CrossRef]
- Lu, Y.; Lu, J.; Li, X.; Zhu, H.; Fan, X.; Zhu, S.; Wang, Y.; Guo, Q.; Wang, L.; Huang, Y.; et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer 2014, 14, 85. [Google Scholar] [CrossRef]
- Jiang, J.; Li, Z.; Yu, C.; Chen, M.; Tian, S.; Sun, C. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett. 2015, 356, 962–970. [Google Scholar] [CrossRef]
- Jiang, J.; Yu, C.; Chen, M.; Zhang, H.; Tian, S.; Sun, C. Reduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype. Oncotarget 2015, 6, 2767–2778. [Google Scholar] [CrossRef]
- Zhao, Y.; Zhao, L.; Ischenko, I.; Bao, Q.; Schwarz, B.; Niess, H.; Wang, Y.; Renner, A.; Mysliwietz, J.; Jauch, K.W.; et al. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target Oncol. 2015, 10, 535–548. [Google Scholar] [CrossRef]
- Cioffi, M.; Trabulo, S.M.; Sanchez-Ripoll, Y.; Miranda-Lorenzo, I.; Lonardo, E.; Dorado, J.; Reis Vieira, C.; Ramirez, J.C.; Hidalgo, M.; Aicher, A.; et al. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut 2015, 64, 1936–1948. [Google Scholar] [CrossRef] [PubMed]
- Ma, C.; Ding, Y.C.; Yu, W.; Wang, Q.; Meng, B.; Huang, T. MicroRNA-200c overexpression plays an inhibitory role in human pancreatic cancer stem cells by regulating epithelial-mesenchymal transition. Minerva Med. 2015, 106, 193–202. [Google Scholar] [PubMed]
- Zhou, W.; Li, Y.; Gou, S.; Xiong, J.; Wu, H.; Wang, C.; Yan, H.; Liu, T. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/beta-catenin pathway. Oncotarget 2015, 6, 37557–37569. [Google Scholar] [CrossRef]
- Tsukasa, K.; Ding, Q.; Miyazaki, Y.; Matsubara, S.; Natsugoe, S.; Takao, S. miR-30 family promotes migratory and invasive abilities in CD133(+) pancreatic cancer stem-like cells. Hum. Cell 2016, 29, 130–137. [Google Scholar] [CrossRef]
- Li, P.; Xu, Q.; Zhang, D.; Li, X.; Han, L.; Lei, J.; Duan, W.; Ma, Q.; Wu, Z.; Wang, Z. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. FEBS Lett. 2014, 588, 705–712. [Google Scholar] [CrossRef]
- Lee, C.J.; Dosch, J.; Simeone, D.M. Pancreatic cancer stem cells. J. Clin. Oncol. 2008, 26, 2806–2812. [Google Scholar] [CrossRef]
- Ercan, G.; Karlitepe, A.; Ozpolat, B. Pancreatic cancer stem cells and therapeutic approaches. Anticancer Res. 2017, 37, 2761–2775. [Google Scholar] [CrossRef]
- Zhan, H.X.; Xu, J.W.; Wu, D.; Zhang, T.P.; Hu, S.Y. Pancreatic cancer stem cells: New insight into a stubborn disease. Cancer Lett. 2015, 357, 429–437. [Google Scholar] [CrossRef]
- Tesfaye, A.; Azmi, A.S.; Philip, P.A. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Am. J. Pathol. 2019, 189, 58–70. [Google Scholar] [CrossRef]
- Singh, S.; Chitkara, D.; Kumar, V.; Behrman, S.W.; Mahato, R.I. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett. 2013, 334, 211–220. [Google Scholar] [CrossRef]
- Jung, D.E.; Wen, J.; Oh, T.; Song, S.Y. Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas 2011, 40, 1180–1187. [Google Scholar] [CrossRef]
- Ji, Q.; Hao, X.; Zhang, M.; Tang, W.; Yang, M.; Li, L.; Xiang, D.; Desano, J.T.; Bommer, G.T.; Fan, D.; et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009, 4, e6816. [Google Scholar] [CrossRef] [PubMed]
- Biondani, G.; Zeeberg, K.; Greco, M.R.; Cannone, S.; Dando, I.; Dalla Pozza, E.; Mastrodonato, M.; Forciniti, S.; Casavola, V.; Palmieri, M.; et al. Extracellular matrix composition modulates PDAC parenchymal and stem cell plasticity and behavior through the secretome. FEBS J. 2018, 285, 2104–2124. [Google Scholar] [CrossRef] [PubMed]
- Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313–323. [Google Scholar] [CrossRef]
- Olempska, M.; Eisenach, P.A.; Ammerpohl, O.; Ungefroren, H.; Fandrich, F.; Kalthoff, H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat. Dis. Int. 2007, 6, 92–97. [Google Scholar]
- Marechal, R.; Demetter, P.; Nagy, N.; Berton, A.; Decaestecker, C.; Polus, M.; Closset, J.; Deviere, J.; Salmon, I.; Van Laethem, J.L. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br. J. Cancer 2009, 100, 1444–1451. [Google Scholar] [CrossRef]
- Ikenaga, N.; Ohuchida, K.; Mizumoto, K.; Yu, J.; Kayashima, T.; Hayashi, A.; Nakata, K.; Tanaka, M. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas. Hum. Pathol. 2010, 41, 1466–1474. [Google Scholar] [CrossRef]
- Huang, P.; Wang, C.Y.; Gou, S.M.; Wu, H.S.; Liu, T.; Xiong, J.X. Isolation and biological analysis of tumor stem cells from pancre- atic adenocarcinoma. World J. Gastroenterol. 2008, 14, 3903–3907. [Google Scholar] [CrossRef]
- Li, C.; Wu, J.J.; Hynes, M.; Dosch, J.; Sarkar, B.; Welling, T.H.; Pasca di Magliano, M.; Simeone, D.M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141, 2218–2227.e2215. [Google Scholar] [CrossRef]
- Droz, D.; Zachar, D.; Charbit, L.; Gogusev, J.; Chretein, Y.; Iris, L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am. J. Pathol. 1990, 137, 895–905. [Google Scholar]
- Poncet, C.; Frances, V.; Gristina, R.; Scheiner, C.; Pellisier, J.F.; Branger, F.B. CD24, a glycosylphosphatidylinositol-anchored molecule, is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors. Acta Neuropathol. 1996, 91, 400–408. [Google Scholar] [CrossRef] [PubMed]
- Gzil, A.; Zarębska, I.; Bursiewicz, W.; Antosik, P.; Grzanka, D.; Szylberg, L. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol. Biol. Rep. 2019, 46, 6629–6645. [Google Scholar] [CrossRef] [PubMed]
- Jacob, J.; Bellach, J.; Grützmann, R.; Alldinger, I.; Pilarsky, C.; Dietel, M.; Kristiansen, G. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 2004, 4, 454–460. [Google Scholar] [CrossRef]
- Boivin, D.; Labbé, D.; Fontaine, N.; Lamy, S.; Beaulieu, E.; Gingrans, D.; Beliveau, R. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 2009, 48, 3998–4007. [Google Scholar] [CrossRef] [PubMed]
- Taïeb, N.; Maresca, M.; Guo, X.-J.; Garmy, N.; Fantini, J.; Yahi, N. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett. 2009, 278, 164–173. [Google Scholar] [CrossRef]
- Röper, K.; Corbeil, D.; Huttner, W.B. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat. Cell Biol. 2000, 2, 582–592. [Google Scholar] [CrossRef] [PubMed]
- Giebel, B.; Corbeil, D.; Beckmann, J.; Hohn, J.; Freund, D.; Giesen, K.; Fischer, J.; Kogler, G.; Wernet, P. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004, 104, 2332–2338. [Google Scholar] [CrossRef]
- Zhan, T.; Rindtorff, N.; Boutros, M. Wnt signaling in cancer. Oncogene 2017, 36, 1461–1473. [Google Scholar] [CrossRef]
- Jiang, X.; Hao, H.-X.; Growney, J.D.; Woolfenden, S.; Bottiglio, C.; Ng, N.; Lu, B.; Hsieh, M.H.; Bagdasarian, L.; Meyer, R.; et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 2013, 110, 12649–12654. [Google Scholar] [CrossRef]
- Chen, X.; Cheng, F.; Liu, Y.; Zhang, L.; Song, L.; Cai, X.; You, T.; Fan, X.; Wang, D.; Gong, A.; et al. Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1. EBioMedicine 2019, 40, 135–150. [Google Scholar] [CrossRef]
- Hou, Y.-C.; Chao, Y.-J.; Tung, H.-L.; Wang, H.C.; Shan, Y.S. Co-expression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer 2014, 120, 2766–2777. [Google Scholar] [CrossRef] [PubMed]
- Banerjee, S.; Nomura, A.; Sangwan, V.; Chugh, R.; Dudeja, V.; Vickers, S.M.; Saluja, A. CD133 + tumor initiating cells (TIC) in a syngenic murine model of pancreatic cancer respond to Minnelide. Clin. Cancer Res. 2014, 20, 2388–2399. [Google Scholar] [CrossRef] [PubMed]
- Xin, B.; He, X.; Wang, J.; Cai, J.; Wei, W.; Zhang, T.; Shen, X. Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer. Pancreatology 2016, 16, 1005–1014. [Google Scholar] [CrossRef] [PubMed]
- Huber, M.A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Investig. 2004, 114, 569–581. [Google Scholar] [CrossRef]
- Nomura, A.; Banerjee, S.; Sangwan, V.; Chugh, R.; Dudeja, V.; Vickers, S.M.; Saluja, A.K. CD133 initiates tumors, induces epithelial-mesenchymal transition, and increases metastasis in pancreatic cancer. Cancer Res. 2015, 75, A24. [Google Scholar] [CrossRef]
- Hashimoto, O.; Shimizu, K.; Semba, S.; Chiba, S.; Ku, Y.; Yokozaki, H.; Hori, Y. Hypoxia induces tumor aggressiveness and the ex- pansion of CD133-positive cells in a hypoxia-inducible factor- 1alpha-dependent manner in pancreatic cancer cells. Pathobiology 2011, 78, 181–192. [Google Scholar] [CrossRef]
- Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2014, 64, 9–29. [Google Scholar] [CrossRef]
- World Health Organization. World Cancer Report; WHO: Geneva, Switzerland, 2014; Chapter 5.7; ISBN 978-92-832-0429-9. [Google Scholar]
- Chen, C.; Zhao, S.; Karnad, A.; Freeman, J.W. The biology and role of CD44 in cancer progression: Therapeutic implications. J. Hematol. Oncol. 2018, 11, 64. [Google Scholar] [CrossRef]
- Cho, S.H.; Park, Y.S.; Kim, H.J.; Kim, C.H.; Lim, S.W.; Huh, J.W.; Lee, J.H.; Kim, H.R. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int. J. Oncol. 2012, 4, 211–218. [Google Scholar] [CrossRef]
- Ponta, H.; Sherman, L.; Herrlich, P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4, 33–45. [Google Scholar] [CrossRef]
- Brown, R.L.; Reinke, L.M.; Damerow, M.S.; Perez, D.; Chodosh, L.A.; Yang, J.; Cheng, C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Investig. 2011, 121, 1064–1074. [Google Scholar] [CrossRef] [PubMed]
- Bourguignon, L.Y.W.; Wong, G.; Earle, C.; Chen, L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J. Biol. Chem. 2012, 287, 32800–32824. [Google Scholar] [CrossRef] [PubMed]
- Bourguignon, L.Y.W.; Earle, C.; Wong, G.; Spevak, C.C.; Krueger, K. Stem cell marker (Nanog) and Stat-3 signaling promote microRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012, 31, 149–160. [Google Scholar] [CrossRef] [PubMed]
- Bourguignon, L.Y.W.; Spevak, C.C.; Wong, G.; Xia, W.; Gilad, E. Hyaluronan-CD44 interaction with protein kinase Cϵ promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 2009, 284, 26533–26546. [Google Scholar] [CrossRef]
- Shiina, M.; Bourguignon, L.Y.W. Selective activation of cancer stem cells by size-specific hyaluronan in head and neck cancer. Int. J. Cell Biol. 2015, 2015. [Google Scholar] [CrossRef]
- Cheng, W.; Liu, T.; Wan, X.; Gao, Y.; Wang, H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012, 279, 2047–2059. [Google Scholar] [CrossRef]
- Grzywa, T.M.; Klicka, K.; Włodarski, P.K. Regulators at Every Step-How microRNAs Drive Tumor Cell Invasiveness and Metastasis. Cancers 2020, 12, 3709. [Google Scholar] [CrossRef]
- Koshiba, T.; Hosotani, R.; Miyamoto, Y.; Ida, J.; Tsuji, S.; Nakajima, S.; Kawaguchi, M.; Kobayashi, H.; Doi, R.; Hori, T.; et al. Expression of stromal cell-derived factor 1 and CXCR106 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin. Cancer Res. 2000, 6, 3530–3535. [Google Scholar]
- Gao, Z.; Wang, X.; Wu, K.; Zhao, Y.; Hu, G. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR107 axis. Pancreatology 2010, 10, 186–193. [Google Scholar] [CrossRef]
- Marchesi, F.; Monti, P.; Leone, B.E.; Zerbi, A.; Vecchi, A.; Piemonti, L.; Mantovani, A.; Allavena, P. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR108. Cancer Res. 2004, 64, 8420–8427. [Google Scholar] [CrossRef]
- Deng, S.; Yang, X.; Lassus, H.; Liang, S.; Kaur, S.; Ye, Q.; Li, C.; Wang, L.P.; Roby, K.F.; Orsulic, S.; et al. Distinct expression levels and pat- terns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 2010, 5, e10277. [Google Scholar] [CrossRef] [PubMed]
- Jimeno, A.; Feldmann, G.; Suarez-Gauthier, A.; Rasheed, Z.; Solomon, A.; Zou, G.M.; Rubio-Viqueira, B.; Garcia-Garcia, E.; Lopez-Rios, F.; Matsui, W.; et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic de- velopment. Mol. Cancer Ther. 2009, 8, 310–314. [Google Scholar] [CrossRef] [PubMed]
- Rausch, V.; Liu, L.; Kallifatidis, G.; Baumann, B.; Mattern, J.; Gladkich, J.; Wirth, T.; Schemmer, P.; Buchler, M.W.; Zoller, M.; et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010, 70, 5004–5013. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Xu, X.; Shi, M.; Chen, Y.; Yu, D.; Zhao, C.; Gu, Y.; Yang, B.; Guo, S.; Ding, G.; et al. CD13hi Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Oncoimmunology 2017, 6, e1258504. [Google Scholar] [CrossRef] [PubMed]
- Khaled, Y.S.; Ammori, B.J.; Elkord, E. Myeloid-derived suppressor cells in cancer: Recent progress and prospects. Immunol. Cell Biol. 2013, 91, 493–502. [Google Scholar] [CrossRef]
- Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12, 253–268. [Google Scholar] [CrossRef]
- Dart, D.A.; Arisan, D.E.; Owen, S.; Hao, C.; Jiang, W.G.; Uysal-Onganer, P. Wnt-11 Expression Promotes Invasiveness and Correlates with Survival in Human Pancreatic Ductal Adenocarcinoma. Genes 2019, 10, 921. [Google Scholar] [CrossRef]
- Arisan, E.D.; Rencuzogullari, O.; Cieza-Borrella, C.; Miralles Arenas, F.; Dwek, M.; Lange, S.; Uysal-Onganer, P. MiR-21 Is Required for the Epithelial–Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells. Int. J. Mol. Sci. 2021, 22, 1557. [Google Scholar] [CrossRef]
- Moriyama, T.; Ohuchida, K.; Mizumoto, K.; Yu, J.; Sato, N.; Nabae, T.; Takahata, S.; Toma, H.; Nagai, E.; Tanaka, M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009, 8, 1067–1074. [Google Scholar] [CrossRef]
- Huo, W.; Zhao, G.; Yin, J.; Ouyang, X.; Wang, Y.; Yang, C.; Wang, B.; Dong, P.; Wang, Z.; Watari, H.; et al. Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J. Cancer 2017, 8, 57–64. [Google Scholar] [CrossRef]
- Yue, J.; Sheng, Y.; Ren, A.; Penmatsa, S. A miR-21 hairpin structure-based gene knockdown vector. Biochem. Biophys. Res. Commun. 2010, 394, 667–672. [Google Scholar] [CrossRef]
- Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
Cancer Stem Cell Markers | Control | Panc-1 KO2 | KO4 | Control | MiaPaCa-2 KO2 | KO4 |
---|---|---|---|---|---|---|
CD24+ CD13+ | 97.4% | 0% | 0% | 11.8% | 0% | 0% |
CD24− CD13− | 0% | 95.6% | 99.8% | 6.3% | 96.4% | 97.7% |
CD24+ CD13− | 2.6% | 4.3% | 0.1% | 81.9% | 3.6% | 2.3% |
CD24− CD13+ | 0% | 0% | 0.2% | 0% | 0% | 0% |
Primer | Forward Sequence (5′–3′) | Reverse Sequence (5′–3′) |
---|---|---|
E-cadherin | AAGAAGCTGGCTGACATGTACGGA | CCACCAGCAACGTGATTTCTGCAT |
Wnt-11 | GTGAAGGACTCGGAACTCGT | CTTCTGTTCCTGGTGGCTTC |
Snail | TTTCTGGTTCTGTGTCCTCTGCCT | TGAGTCTGTCAGCCTTTGTCCTGT |
Vimentin | TACAGGAAGCTGCTGGAAGG | ACCAGAGGGAGTGAATCCAG |
Zeb1 | GGGAGGAGCAGTGAAAGAGA | TTTCTTGCCCTTCCTTTCTG |
U6 | GCTTCGGCAGCACATATACTAAAAT | CGCTTCACGAATTTGCGTGTCAT |
RPII | GCACCACGTCCAATGACAT | GTGCGGCTGCTTCCATAA |
CD133 | AAGCATTGGCATCTTCTATGG | AAGCACAGAGGGTCATTGAGA |
CD24 | GAAAACTGAATCTCCATTCCACAA | TGAAGAACATGTGAGAGGTTTGAC |
CD44 | CCAGAAGGAACAGTGGTTTGGC | ACTGTCCTCTGGGCTTGGTGTT |
ALDH1 | ATCAAAGAAGCTGCCGGGAA | TCTTAGCCCGCTCAACACTC |
CXCR4 | GCCAACCATGATGTGCTGAAAC | GCCAACGTCAGTGAGGCAGA |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mortoglou, M.; Miralles, F.; Arisan, E.D.; Dart, A.; Jurcevic, S.; Lange, S.; Uysal-Onganer, P. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. Int. J. Mol. Sci. 2022, 23, 1275. https://doi.org/10.3390/ijms23031275
Mortoglou M, Miralles F, Arisan ED, Dart A, Jurcevic S, Lange S, Uysal-Onganer P. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 2022; 23(3):1275. https://doi.org/10.3390/ijms23031275
Chicago/Turabian StyleMortoglou, Maria, Francesc Miralles, Elif Damla Arisan, Alwyn Dart, Stipo Jurcevic, Sigrun Lange, and Pinar Uysal-Onganer. 2022. "microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells" International Journal of Molecular Sciences 23, no. 3: 1275. https://doi.org/10.3390/ijms23031275
APA StyleMortoglou, M., Miralles, F., Arisan, E. D., Dart, A., Jurcevic, S., Lange, S., & Uysal-Onganer, P. (2022). microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences, 23(3), 1275. https://doi.org/10.3390/ijms23031275